Protagenic Therapeutics, Inc.PTIX

Protagenic Therapeutics, Inc. operates as a biopharmaceutical firm dedicated to the research and development of novel treatments designed to address neuropsychiatric and mood conditions exacerbated by stress. Foremost among its investigational products is PT00114, a laboratory-synthesized version of the teneurin carboxy-terminal associated peptide. This compound functions by emulating an innate brain signaling peptide, known for its ability to temper exaggerated stress reactions. The company's headquarters are located in New York, New York.